A fourth revision of the McDonald diagnostic criteria is currently underway to address some of the conceptual and practical difficulties in the diagnosis of multiple sclerosis, according to Dr. Jeffrey Cohen, Cleveland Clinic, Cleveland, Ohio. His remarks were made at the 43^rd International Neuroscience Symposium of the Université de Montréal, held May 3-5, 2022, in Montreal. Read More

Recent imaging studies in multiple sclerosis have focused on the association between cognitive dysfunction and grey-matter tissue loss, most notably of the cerebral cortex and thalamus. For example, at the American Academy of Neurology annual meeting, an analysis of the SPRINT-MS trial proposed that lower thalamic volume at baseline may be a useful predictor of physical, cognitive and visual disability in progressive MS (Nicholson et al. AAN 2022;S12.007). Thalamic volume at the time of relapse may also be predictive of cognitive recovery as assessed by the Symbol Digit Modalities Test (SDMT) (Weinstock et al. AAN 2022;P14.010). As such, thalamic volume (but not T2 lesion volume in this study) may serve as a marker of cognitive reserve. Read More

A number of new studies have provided data on the long-term safety and efficacy of high-efficacy disease-modifying therapies in MS. The data were presented at the American Academy of Neurology (AAN) annual meeting, held April 2-7 in Seattle, Washington. The following is a summary of key studies. Read More

Selected highlights from the American Academy of Neurology annual meeting, Seattle WA, 2-7 April 2022.

April 5 Edition
April 4 Edition

SPMS undertreated
NEDA not preditive of disability in RMS
Emerging concepts: spinal cord reserve
Thalamic volume affects cognitive recovery
Alemtuzumab in PMS
Clinical practice Read More